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Abstract
Stem cells are characterized based on two basic characteristics—a capability 
for self-renewal and a capability to develop into specialized cells. The 
type of specialization often depends on the cell’s function and location, 
such as those of acid and protein secreting cells in the stomach or insulin 
secreting cells in the pancreas. On the other hand, the capability for self-
renewal and specialization enables a nerve stem cell, for example, to grow 
into a mature nerve cell and another self-renewing cell that perpetuates 
the next cycle of self replication and specialization. Stem cells can also 
be categorized into embryonic stem cells and adult stem cells. Pluripotent 
embryonic stem cells are derived from the inner cell mass of the blastocyst 
and adult stem cells are undifferentiated cells found in post-embryonic 
tissues or organs. The primary roles of adult stem cells are to maintain 
and repair the tissues or organs in which they reside. The pluripotency of 
embryonic stem cells, which give rise to various cell types, and the ability of 
adult stem cells to repair tissue damage are the “magic fix” that regeneration 
medicine is suggesting. Whether the function of stem cells is hematopoietic 
or non-hematopoietic, researchers all over the world are striving hard to 
harness the use of stem cells for medicine. As the progress of stem cell 
research moves steadily forward, let us pause for a minute and pose a 
question. Are stem cells really going to be the magical medical therapeutic 
component of the future? [Tzu Chi Med J 2009;21(1):12–17]
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1. Introduction
A recent report in Science describing a breakthrough 
in the conversion of human somatic cells into pluripo-
tent embryonic stem cell lines by the introduction of 
four genes [1] has stirred up a new wave of inspiration 
and enthusiasm in stem cell technology and stem 
cell therapy. Concomitantly, a similar report appearing 
in the journal Cell made similar observations on the 
generation of induced pluripotent stem cells by the 
transduction of four defined transcription factors [2]. 
But what are stem cells? Why are they getting so much 
attention from the general public and professionals 
alike, and what is so special about them?
According to a report prepared by the United States 
National Institutes of Health [3], stem cells are special 
 TZU CHI MED J  March 2009  Vol 21  No 1 13
cells that possess the unique capacity to renew indefi-
nitely. They can give rise to specialized cell types, 
such as heart cells, nerve cells, muscle cells and skin 
cells, that make up the organism. In addition, stem 
cells are uncommitted progenitors that remain un-
committed until they receive signals to develop into 
specialized cells to perform their committed biological 
functions [3].
Three types of stem cells have now been identified— 
embryonic stem cells, embryonic germ cells, and adult 
stem cells. Embryonic stem cells are obtained from 
a group of cells called the inner cell mass, which is 
part of the early stage of the embryo termed the 
blastocyst (a blastocyst is developed from a fertilized 
egg). Embryonic germ cells are derived from the pri-
mordial germ cells of the gonadal ridge of a 5–10-week-
old fetus. Adult stem cells are undifferentiated cells 
in a postembryonic differentiated tissue or organ and 
are capable of renewing themselves and producing 
specialized cell types of the tissue or organ from which 
they originate [3]. Adult stem cells derive from a wide 
range of tissues and may exist in every major tissue 
type. For example, umbilical cord blood (UCB) and the 
umbilical cord (UC) [4–8], placenta [9,10], mammary 
gland [11], olfactory bulb [12], adipose tissue [13,14], 
heart [15], central nervous system [16], epidermis 
[17,18], hair follicle [18], eye [19,20], bone marrow 
[4,21,22], and teeth [23,24] have all been reported 
to contain adult stem cells. A well recognized adult stem 
cell is the bone marrow supportive element called the 
mesenchymal stem cell (MSC). MSCs display enormous 
expansion ability and, under appropriate circumstances, 
can differentiate into neuronal, muscle, adipose, car-
diac and cartilage cells [3]. These are the types of cells 
that cell-based therapy intends to exploit for thera-
peutic applications [4,21,22]. Other applications for 
MSCs have focused on immune regulation. Ex vivo-
expanded MSCs isolated from humans have been 
demonstrated to suppress the activity of immune cells 
including T cells, B cells, antigen presenting cells and 
natural killer cells [3,25]. This potential function of 
MSCs is of value in the taming of graft rejection and 
graft versus host disease, which inevitably occur in 
bone marrow transplantation [3].
Functionally speaking, stem cells may be totipo-
tent or pluripotent. The totipotent cells of the very 
early embryo have the capacity to differentiate into 
all postembryonic tissues and organs while pluripotent 
stem cells have the capacity to give rise to cells of all 
three germ layers of the embryo—the ectoderm, en-
doderm and mesoderm. Generally speaking, embryonic 
stem cells at days 4–5 are considered to be totipotent, 
whereas inner cell mass embryonic stem cells, em-
bryonic germ cells and adult stem cells are regarded 
as pluripotent [3]. Therefore, it is the capacity and the 
plasticity of the stem cells that has received attention 
in recent years and the term stem cell was considered 
unequivocally equal to regenerative medicine or, to 
use a lay term, a “magic wonder”.
What evidence do we have, however that embryonic 
stem cells and adult stem cells hold promise for cellular 
therapy? The following few reports are noteworthy.
2. Myocardial infarction
Today, despite improvements in pharmacologic and 
invasive treatment, myocardial infarction and ische-
mic heart failure are still leading causes of morbidity 
and mortality worldwide. An article published in Cyto-
therapy demonstrated that transplantation of em-
bryonic stem cell-derived cardiomyocytes improves 
cardiac function in infarcted rat hearts [26]. Another 
report found that injection of bone marrow cells in the 
peri-infarcted left ventricle of mice resulted in myo-
cardial regeneration [27]. Additionally, recent studies 
by Henning et al [28] and Hirata et al [29] described 
the application of human UCB in treating acute myo-
cardial infarction in rats. Both groups of researchers 
injected UCB mononuclear cells immediately after 
coronary artery occlusion in rats. Compared with the 
controls, the animals treated with UCB cells had re-
duced infarct size, and improved myocardial contrac-
tility and ejection fractions [28,29]. After reviewing an 
array of studies in humans, the author of an editorial 
in the New England Journal of Medicine noted that, 
although the ability of infused bone marrow cells to 
generate cardiomyocytes may be questioned and only 
a remnant amount of the transplanted cells remained 
in the heart, cytokines or growth factors through para-
crine secretion could indirectly promote mobilization 
of endogenous progenitors to the vicinity of the lesion 
area to repair damage and initiate angiogenesis. How-
ever, a failure of cell therapies to achieve a therapeu-
tic effect on cardiac injury was also observed. The 
author rationalized that the heterogeneity of bone 
marrow cell populations applied for treatment were 
to be considered for various outcomes in cell therapy. 
This helps explain why similar treatment protocols 
can yield different results [30]. It appears, therefore, 
that transplantation using embryonic stem cells, bone 
marrow cells and UCB cells could offer alternative 
cell therapies for the repair of necrotic myocardium. 
All these studies suggest that embryonic and adult 
stem cells may be potentially valuable for the regen-
eration of an infarcted heart.
3. Cerebral stroke
Cerebral stroke is a medical emergency and can 
cause permanent neurological damage and death if 
not promptly diagnosed and treated. It is a leading 
cause of death and adult disability in many countries. 
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To combat this devastating traumatic brain injury, at-
tention has turned to stem cell therapy. Vendrame et al 
[31] reported on the infusion of human UCB cells in 
a rat model of stroke. The treatment dose-dependently 
reduced behavioral deficits and the infarct volume. 
Similarly, in a severe combined immune deficient 
mouse model, CD34+-selected cord blood cells were 
injected into middle cerebral artery occlusion-inflicted 
rats 48 hours after stroke. Neovascularization at the 
border of the ischemic zone was observed, followed by 
endogenous neurogenesis [32]. Further animal studies 
and clinical trials in humans are necessary to con-
solidate the efficacy and safety of stem cell therapy 
for stroke patients. Nevertheless, at this time, one may 
be cautiously optimistic about the future promise of 
stem cell therapy for cerebral stroke.
4. Spinal cord injury
The prevalence of spinal cord injury (SCI) is increasing 
as a result of motor vehicle accidents, violence, falls 
and diving accidents. Spinal cord injury causes damage 
to white matter or myelinated fibers that carry sensa-
tion and motor signals to and from the brain. It also 
causes damage to gray matter in the central region of 
the spine causing segmental losses of interneurons 
and motoneurons. In addition to the loss of motor 
function and sensation below the point of injury, in-
dividuals with SCI often experience other complica-
tions. Undoubtedly, any medical treatment that can 
alleviate SCI and help patients with SCI regain mobility 
will be welcome. In an animal study that used rhesus 
monkeys, implantation of bone marrow MSCs gener-
ated de novo neurogenesis and the SCI inflicted ani-
mals achieved functional recovery [33]. In humans, 
Kang et al [34] described a patient with SCI who was 
transplanted with multipotent stem cells from human 
UC blood. The patient showed improved sensory per-
ception and mobility both functionally and morpho-
logically 19 years and 6 months after the spinal cord 
injury [34]. Although there have been few successful 
outcomes with MSC and cord blood transplantations 
in SCI, the results definitely inspire high hopes for 
a curative medical treatment for this condition.
5. Duchenne muscular dystrophy
The muscular dystrophies are a group of genetic and 
hereditary muscle diseases characterized by defects 
in muscle proteins, progressive skeletal muscle weak-
ness and death of muscle cells and tissues resulting 
from mutations of genes responsible for the dystro-
phin protein. In some forms of muscular dystrophy, 
smooth muscle and cardiac muscle are affected. One 
of the major types of muscular dystrophy is called 
Duchenne muscular dystrophy (DMD), which is a fatal 
X chromosome-linked muscle dystrophy that affects 
juvenile males. The most frequent symptoms are skel-
etal and muscle deformities and frequent falls, walking 
problems and eyelid drooping due to muscle weakness 
[35,36]. To date, no known drug can stop muscle 
dystrophy, but cell-based therapies may offer a poten-
tial treatment. As in human DMD, the mdx mouse 
(C57BL/10ScSn) lacks dystrophin in its skeletal muscle 
fibers, which makes it a useful animal model for DMD 
research [35,36]. In animal studies [35,36], bone 
marrow stem cells were injected into the tail veins of 
irradiated experimental mdx mice to determine the 
effects of the transplanted cells. Expression of dys-
trophin and MyoD (a master regulatory gene for skeletal 
myogenesis) was detected at different time points by 
immunofluorescence staining, Western blotting and 
reverse transcription-polymerase chain reaction [35]. 
The investigation found that bone marrow cells were 
recruited to the muscles of the experimental mice and 
the injected cells proceeded to muscle differentiation, 
recapitulating embryonic myogenesis, which partially 
restored the specific pathophysiologic features of dys-
trophic muscle in aged mdx mice [35]. Although it is 
too early to consider stem cells as a promising treat-
ment for DMD, this report did suggest that bone marrow 
stem cell transplantation may be potentially useful as 
an alternative therapeutic approach for this condition.
6. Type 1 diabetes
The potential application of allogeneic bone marrow 
stem cell transplantation to alter the course of the 
type 1 diabetes mellitus (DM) disease process was first 
proposed in animal studies in the 1980s [37] and there 
were calls for bone marrow transplantation (BMT) to be 
tested in treating this disorder in the early part of the 
present decade. Autologous human stem cell trans-
plantation for type 1 DM proposed by Voltarelli et al [38] 
involved stem cell mobilization of peripheral blood 
CD34+ cells, immune ablation in the recipient to elim-
inate self-reactive lymphocytes within the body, and 
reinfusion and cryopreservation of autologous stem 
cells harvested in the beginning. The study demon-
strated significant improvements in beta cell function, 
as measured by C-peptide levels. There were several 
limitations, however, which included uncertainty over 
whether the putative beneficial effects of the autologous 
stem cell transplant were due to immune reconstitution 
or otherwise altering the immune-mediated beta cell 
destruction that eventuates in the type 1 DM disease 
process, or were due to regeneration of beta cells [38]. 
Other approaches under consideration include the use 
of umbilical cord cells [39], embryonic or adult stem 
cells [40] and allogeneic BMT [41,42]. For bone marrow 
transplantation in rats with diabetes, it was further 
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suggested that successful treatment with bone marrow 
and mesenchymal stem cells occurred because both 
types of cells induced regeneration of recipient-derived 
pancreatic insulin-secreting cells and because mes-
enchymal stem cells were able to inhibit the T cell-
mediated immune response against beta cells [42]. 
Research in this area is likely to increase in the near 
future and curative therapy for type 1 DM may soon 
become possible.
7. Parkinson’s disease
Parkinson’s disease is one of the most common neu-
rodegenerative diseases, and it is characterized by the 
progressive loss of dopamine neurons in the substantia 
nigra of the midbrain. One of the therapeutic successes 
in the treatment of this disease has been the use of 
L-dopa. However, dopamine replacement fails to slow 
the rate of loss of neurons, and the beneficial effects 
wear off with time. Surgical treatment is not a better 
option because the unstable efficiency and shortage 
of donated embryonic mesencephalic tissue limit the 
application of embryonic tissue transplantation as a 
therapeutic option. Therefore, recent advances in stem 
cell research have inspired high hopes for cell based 
therapy as the answer to this disease [43,44]. Three 
types of stem cells (neural stem cells, mesenchymal 
stem cells and embryonic stem cells) are currently being 
tested in stem cell therapy for Parkinson’s disease. 
Parish et al [45] found that, using in vitro differentia-
tion of Cripto(−/−), embryonic stem cells resulted in an 
increase in dopaminergic differentiation and, upon 
transplantation into 6-OHDA lesioned Parkinson’s rats, 
facilitated behavioral and anatomical recovery in the 
animals tested. Using tyrosine hydroxylase and GTP 
cyclohydrolase 1 transduced human neuronal stem cells 
in brain transplantation of Parkinsonian rats, Kim et al 
[46] reported functional improvement in animal models 
of Parkinson’s disease. Similarly, mesenchymal stem 
cells derived from bone marrow and umbilical cord 
were reported to be capable of producing functional 
benefits in animals with Parkinson’s disease [43]. Will 
stem cell therapy for Parkinson’s disease in humans 
be as successful? We hope that regulated clinical trials 
can answer this critical question.
8. Stem cell engineering
Stem cells in tissue engineering are aimed at producing 
“spare parts” for the body to replace damaged or de-
stroyed tissues and organs. Despite questions about 
the actual clinical feasibility of the “engineered parts”, 
the potential for tissue engineering to produce blood 
vessels, skin, nasal cartilage, urinary bladders, and 
cardiac valves is increasing [47]. In addition, efforts 
to generate neuronal cells to produce dopamine for 
patients with Parkinson’s disease and to cultivate cells 
of oligodendrocyte lineages for patients with multiple 
sclerosis may one day materialize and prove successful 
in cellular therapy [48]. Other applications in tissue 
engineering of stem cells include the generation of skin 
for skin grafting, formation of bones for bone recon-
struction, identification and isolation of stem cells from 
various tissues to provide appropriate targets for pro-
spective gene therapies [47], and restoration of dam-
aged corneas using stem cells derived from autologous 
or allogeneic limbal epithelial cells [49,50]. Stem cell 
engineering offers an avenue of therapeutic options, 
which depend on the collaborative efforts of devoted 
scientists and medical personnel.
9. Discussion
Today, it does seem that stem cell therapy has potential 
clinical relevance in tissue regeneration. Organ repair 
is not a matter of a quick fix for various diseases and 
we are not even near the stage when the efficacy and 
safety of cell-based therapies are a matter of reality. 
In fact, there are questions about the coming of age 
of stem cell therapy [51–53]. However, there have been 
successful outcomes in bone marrow, peripheral blood 
stem cells (PBSC) and UCB hematopoietic stem cell 
transplantations, which were performed to treat severe 
anemia, metabolic disorders, immune deficiency and 
blood cancers. Since its successful debut 40 years ago, 
bone marrow transplantation has been used to treat 
patients diagnosed with aplastic anemia, leukemia, 
immune deficiency disorders, lymphomas and some 
forms of solid tumor [3]. With the advent of advanced 
technologies for PBSC and cryopreservation of UCB, 
hematopoietic stem cell transplantation offers a life-
saving cellular therapy for those facing life-threatening 
diseases. Less than 1 month after the report by Yu et al 
[1] on the success of the generation of human embry-
onic pluripotent stem cell lines from somatic cells, 
Hanna et al [54] reported the generation of induced 
pluripotent stem cells from autologous skin to treat 
sickle cell anemia in a mouse model. This immediate 
progress signifies a great leap in overcoming the ob-
stacles of histocompatibility and allogenicity, which are 
frequently encountered in the arena of allogeneic trans-
plantation. On the other hand, using embryonic stem 
cells [55] and pluripotent stem cells [56] for treatment 
may result in the formation of teratoma or other forms 
of tumorigenicity. This must be carefully evaluated prior 
to actual practice [55,56]. In addition, regulations on 
related issues, such as safety, cell storage and trans-
portation, outcome analysis, equipment supplies, main-
tenance and monitoring, and auditing, must also be 
in place before the clinical introduction of stem cell 
therapy. Vogel [55] stated that it is far from clear when 
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the day of stem cell therapy might arrive. Nevertheless, 
looking back at the history of hematopoietic stem cell 
transplantation of BM, PBSC, and CB provides us with 
optimism about the development of cellular therapy.
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